About
Veritas Genetics transforms genetic data into clinically actionable healthcare insights through cutting-edge whole genome and whole exome sequencing. Their service portfolio spans three core areas: Preventive Medicine (including disease risk scoring, polygenic risk screening, and pharmacogenomics), Perinatal Medicine (non-invasive prenatal testing, newborn screening, and chromosomal abnormality studies), and Diagnostic Genomics (hereditary cardiovascular disease risk, hereditary cancer risk, and comprehensive sequencing for complex or undiagnosed conditions). Every Veritas test is physician-assisted, requiring a genetic consultation before testing and professional post-test counseling to interpret findings and design future healthcare management plans. This ensures that results are contextualized by experts in genetics rather than delivered without clinical oversight. Generated genomic datasets are stored as a lifetime resource, allowing individuals and their physicians to request reanalysis as new genetic discoveries emerge. Veritas operates across Europe (UK, Spain, Italy, Portugal), Latin America (Brazil, Colombia, Ecuador, Mexico, Argentina), and the UAE, partnering with medical professionals, clinics, and healthcare institutions. Their platform is ideal for patients with family histories of hereditary disease, healthcare providers seeking advanced diagnostic tools, and health systems investing in preventive genomic medicine.
Key Features
- Whole Genome & Exome Sequencing: Delivers comprehensive DNA analysis covering the full genome or protein-coding exome to detect variants linked to disease risk, hereditary conditions, and drug response.
- Three-Domain Service Portfolio: Covers preventive medicine (myGenome, myGeneticRisk, myPharma), perinatal medicine (myPrenatal, myNewborn, qCarrier), and diagnostic genomics (CancerRisk, CardioRisk, GenomeDx, ExomeDx).
- Mandatory Genetic Counseling: All services include pre- and post-test genetic counseling by medical professionals to guide test selection, interpret results, and develop personalized action plans.
- Lifetime Genomic Resource: Raw genomic data is stored and can be reanalyzed in the future as new genetic discoveries and clinical guidelines emerge, ensuring long-term value.
- Pharmacogenomics Testing: myPharma provides advanced pharmacogenomic analysis based on clinical guidelines to identify how an individual's genetics affect drug metabolism and response.
Use Cases
- A healthy individual with a family history of hereditary cancer uses myGeneticRisk to assess their personal risk and work with a physician on a prevention plan.
- An expectant mother undergoes myPrenatal non-invasive prenatal testing to screen for chromosomal abnormalities early in pregnancy.
- A hospital's genetics department integrates GenomeDx whole genome sequencing to diagnose patients with complex, unresolved symptoms suggesting a rare genetic origin.
- A pharmacist and physician team use myPharma pharmacogenomic results to tailor medication choices and dosages for a patient with multiple comorbidities.
- A couple planning a family undergoes qCarrier screening to determine whether they are both carriers of the same monogenic disease before conception.
Pros
- Clinically Rigorous: Mandatory genetic counseling ensures every test is correctly recommended and results are managed by qualified medical professionals, reducing misinterpretation risk.
- Comprehensive Coverage: A single provider covers preventive, perinatal, and diagnostic genetics needs, making it a one-stop solution for medical institutions and patients alike.
- Future-Proof Data: Genomic datasets are retained for life and can be reanalyzed as science advances, offering ongoing value beyond the initial test.
- International Reach: Services are available across Europe, Latin America, and the UAE, making clinical genomics accessible to a wide international patient base.
Cons
- Paid-Only Services: All tests are paid clinical services with no free tier or trial, which may be a barrier for individuals without insurance coverage or high out-of-pocket budgets.
- Requires Physician Involvement: All tests mandate a genetic consultation, meaning patients cannot self-order — this adds time and coordination compared to direct-to-consumer genetic testing.
- Limited Consumer-Facing Transparency: Pricing and specific test details are not readily available on the public website, requiring direct contact, which may slow decision-making.
Frequently Asked Questions
Can I order a Veritas genetic test without a doctor?
No. All Veritas tests require a prior genetic consultation. Veritas can facilitate pre-test genetic counseling to help determine which test is appropriate for your situation.
What is the difference between whole genome sequencing and whole exome sequencing?
Whole genome sequencing (WGS) reads all of a person's DNA, while whole exome sequencing (WES) focuses on the protein-coding regions (exons), which account for most known disease-causing variants. WGS is more comprehensive; WES is more targeted and often used for diagnostic purposes.
What areas of medicine do Veritas services cover?
Veritas covers three main areas: Preventive Medicine (disease risk, pharmacogenomics), Perinatal Medicine (prenatal testing, newborn screening, carrier status), and Diagnostic Genomics (cancer risk, cardiovascular risk, complex undiagnosed conditions).
Can my genomic data be reanalyzed in the future?
Yes. Veritas stores raw genomic data as a lifelong resource. As science advances and new genetic associations are discovered, your data can be reanalyzed to provide updated insights.
In which countries is Veritas Genetics available?
Veritas operates in several European countries (UK, Spain, Italy, Portugal), across Latin America (Brazil, Colombia, Ecuador, Mexico, Argentina), and in the UAE, with services tailored to local regulatory and medical requirements.
